Home
Resources
Publications
Exceptional Responses to Pertuzumab, Trastuzumab, and Docetaxel in Human Epidermal Growth Factor receptor-2 High Expressing Salivary Duct Carcinomas

Exceptional Responses to Pertuzumab, Trastuzumab, and Docetaxel in Human Epidermal Growth Factor receptor-2 High Expressing Salivary Duct Carcinomas

Jong Chul Park, T Martin Ma, Lisa Rooper, Todd Hembrough, Robert D Foss, Nicole C Schmitt, Rishi Sawhney, Aaron Flanders, Hyunseok Kang

Head Neck. 2018 Dec;40(12):E100-E106.

PMID: 30478962

Abstract:

Background:
Alterations in the human epidermal growth factor receptor-2 (HER2) pathway have been identified in a subset of salivary duct carcinomas. Dual HER2 inhibition with trastuzumab and pertuzumab has superior antitumor efficacy to trastuzumab monotherapy in HER2-positive breast cancer, yet its efficacy in HER2-positive salivary duct carcinoma is unknown.
Methods:
We report 2 cases of exceptional responses of HER2-positive salivary duct carcinomas to dual HER2 blockade and docetaxel combination and their molecular characteristics.
Results:
A 54-year-old man with recurrent metastatic HER2 expressing salivary duct carcinoma of the parotid gland after definitive concurrent chemoradiation achieved a complete response (CR) after 6 cycles of trastuzumab, pertuzumab, and docetaxel (TPH). A 42-year-old woman with HER2-positive salivary duct carcinoma of the parotid gland with bone and liver metastases had CR with TPH and remains in remission on maintenance trastuzumab and pertuzumab.
Conclusion:
Dual HER2 blockage resulted in CR in patients with HER expressing salivary duct carcinoma and warrants further evaluation in this patient population.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP21306650	TPh A		21306-65-0	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: